Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Drucker

Showing results (21-30 of 313) with videos related to

Pageof 32
Sort By:
Nature Medicine|January 2, 2026
The expanding landscape of GLP-1 medicinesDaniel J Drucker
Nature Reviews. Drug Discovery|April 25, 2025
GLP-1-based therapies for diabetes, obesity and beyondDaniel J Drucker
Science (New York, N.Y.)|July 18, 2024
The benefits of GLP-1 drugs beyond obesityDaniel J Drucker
Endocrine Reviews|April 16, 2020
Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic ImplicationsDaniel J Drucker
Molecular Endocrinology (Baltimore, Md.)|January 30, 2003
Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosisDaniel J Drucker
Nature Clinical Practice. Endocrinology & Metabolism|August 25, 2006
Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?Daniel J Drucker
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|January 25, 2012
Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disordersDaniel J Drucker
Endocrine Pathology|March 7, 2020
Parathyroid hormone-like peptideDaniel J Drucker
Diabetes Care|June 6, 2024
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and ObesityDaniel J Drucker
Cell Metabolism|September 15, 2016
Never Waste a Good Crisis: Confronting Reproducibility in Translational ResearchDaniel J Drucker
Pageof 32

Showing results (21-30 of 313) with videos related to

Sort By:
Pageof 32
Nature Medicine|January 2, 2026
The expanding landscape of GLP-1 medicinesDaniel J Drucker
Nature Reviews. Drug Discovery|April 25, 2025
GLP-1-based therapies for diabetes, obesity and beyondDaniel J Drucker
Science (New York, N.Y.)|July 18, 2024
The benefits of GLP-1 drugs beyond obesityDaniel J Drucker
Endocrine Reviews|April 16, 2020
Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic ImplicationsDaniel J Drucker
Molecular Endocrinology (Baltimore, Md.)|January 30, 2003
Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosisDaniel J Drucker
Nature Clinical Practice. Endocrinology & Metabolism|August 25, 2006
Does exenatide provide a meaningful new treatment option for patients with type 2 diabetes?Daniel J Drucker
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|January 25, 2012
Essay for the 2011 CIHR/CMAJ award: glucagon-like peptides for metabolic and gastrointestinal disordersDaniel J Drucker
Endocrine Pathology|March 7, 2020
Parathyroid hormone-like peptideDaniel J Drucker
Diabetes Care|June 6, 2024
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and ObesityDaniel J Drucker
Cell Metabolism|September 15, 2016
Never Waste a Good Crisis: Confronting Reproducibility in Translational ResearchDaniel J Drucker
Pageof 32